Article Sidebar
Published:
Jun 23, 2021Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Epimedium brevicornu Maxim extract shows protective activity against Alzheimer's disease in mice
Abstract
Purpose: To investigate the protective effect of Epimedium brevicornu Maxim extract (EBME) against Alzheimer's disease in 3xTg-AD mice.
Methods: The cognitive function of 3xTg-AD mice was assessed using Morris water maze test. The levels of amyloid beta deposits and NeuN in the mouse hippocampus were evaluated by immunohistochemistry. Brain neurotrophic-derived factor (BDNF) and tyrosine kinase B (TrkB) expressions were examined by western blot analysis.
Results: EBME treatment significantly ameliorated learning and memory deficits in AD mice, as shown by the increased time spent in the target zone during probe tests. Compared with the 3xTg-AD mice (8.4 ± 1.1 s), the escape latency in animals treated with 600 mg/kg EBME (21.5 ± 1.1 s) was significantly increased (p < 0.01). In addition, EBME significantly decreased Aβ deposits, increased NeuN-positive cells, and upregulated the expressions of BDNF (1.5 ± 0.2, p < 0.05) and TrkB (1.6 ± 0.2, p < 0.05) in the 3xTg AD mice.
Conclusion: EBME treatment may be a useful therapeutic strategy for managing memory impairment.
